France · Delayed Price · Currency is EUR MedinCell Company Description
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults.
The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia.
Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria.
MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
| Country | France |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Christophe Douat |
Contact Details
Address: 3 rue des FrEres LumiEre Jacou, 34830 France | |
| Phone | 33 4 67 02 13 67 |
| Website | medincell.com |
Stock Details
| Ticker Symbol | MEDCL |
| Exchange | Euronext Paris |
| Fiscal Year | April - March |
| Reporting Currency | EUR |
| ISIN Number | FR0004065605 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christophe Douat | Chief Executive Officer and Director |
| Franck Pouzache | Chief People Officer |
| Stephane Postic | Chief Financial Officer |
| Philippe Moyen | Chief Operating Officer |
| Julie Alimi | General Counsel and Chief Corporate Development Officer |
| David Heuze | Head of Corporate and Financial Communications and ESG |
| Adolfo Lopez-Noriega | Head of Research and Development |
| Sebastien Enault | Chief Business Officer |
| Quiterie De Beauregard | Head of Global Health Development |
| Dr. Richard Malamut M.D. | Chief Medical Officer |